Drug Development Framework

A Contract Award Notice
by CARDIFF UNIVERSITY

Source
Find a Tender
Type
Contract (Services)
Duration
2 year (est.)
Value
___
Sector
INDUSTRIAL
Published
19 Jan 2021
Delivery
To 22 Jan 2023 (est.)
Deadline
n/a

Concepts

Location

Cardiff

Geochart for 2 buyers and 4 suppliers

2 buyers

1 supplier

Description

Cardiff University are ranked 2nd nationally for the impact of their research and are among the top five universities in the UK for research excellence. Cardiff University has a thriving and innovative research culture, with research that has real impact and makes a positive difference to the world. As part of this, the University is translating fundamental discoveries in disease processes to develop new medicines to meet unmet clinical needs. Cardiff University is looking for companies with an innovative outlook and recognised expertise in supporting drug-discovery projects from early screening (electrophysiology and in vitro DMPK) to delivering de-risked novel molecules to clinical trials. Successful companies will be committed to the principles of the NC3Rs and will add value to our work by providing high-quality data for informing the drug-discovery pipeline.

Lot Division

1 Electrophysiology Services

We require providers for electrophysiology services relevant to neuroscience drug development. Currently we require validated ion channel assays for GABAA and NMDA modulators, on an automated electrophysiology platform, with QC and report generation. In the near future, it is likely we will require a range of other ion channel assays, as well as manual patch clamp services. We may also want to purchase ion channel expressing cell lines (under a MTA).
2 In-vivo assays

We require providers for in-vivo assays, most usually with oral administration. We currently require reliable assays for pro-cognitive and anxiolytic effects. In the future, we may require assays to demonstrate other drug modulated effects, such as, but not limited to, an anti-depressive effect.
3 In-vitro drug metabolism (ADME-Tox) services

We require providers of in-vitro drug metabolism (ADME-Tox) services as part of our drug development pipeline. This includes, but is not limited to, measures of metabolism, permeability and transporters, physicochemical properties, protein binding and toxicology.
4 In-vivo pharmacokinetics (PK) and toxicology

We require providers of in-vivo drug metabolism (ADME-Tox) services as part of our drug development pipeline.

Award Detail

1 Unnamed (None)
  • Electrophysiology Services
  • Reference: cu258
  • CONTRACT NOT AWARDED – PROCUREMENT DISCONTINUED.
2 Unnamed (None)
  • In-vivo assays
  • Reference: cu258
  • CONTRACT NOT AWARDED – PROCUREMENT DISCONTINUED.
3 Unnamed (None)
  • In-vitro drug metabolism (ADME-Tox) services
  • Reference: cu258
  • CONTRACT NOT AWARDED – PROCUREMENT DISCONTINUED.
4 Unnamed (None)
  • In-vivo pharmacokinetics (PK) and toxicology
  • Reference: cu258
  • CONTRACT NOT AWARDED – PROCUREMENT DISCONTINUED.

Award Criteria

as per procurement docs 100.0
PRICE _

CPV Codes

  • 73111000 - Research laboratory services

Indicators

  • Award on basis of price.

Other Information

Bidders will need to create an account via In-Tend (https://in-tendhost.co.uk/cardiffuniversity/aspx/Home) in order to view the tender documents. (WA Ref:107445)

Reference

Domains